<DOC>
	<DOCNO>NCT00448682</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , floxuridine , leucovorin , oxaliplatin , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well combination chemotherapy work first-line therapy treat patient stage IV gastric cancer remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy First-Line Therapy Treating Patients With Stage IV Gastric Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall response rate patient unresectable stage IV gastric adenocarcinoma treat floxuridine , leucovorin calcium , oxaliplatin , docetaxel first-line treatment . Secondary - Determine feasibility regimen manage patient unresectable stage IV gastric adenocarcinoma receive prior chemotherapy metastatic disease . - Determine disease-free survival patient treat regimen . - Evaluate overall survival patient treat regimen . - Assess safety toxicity regimen patient . OUTLINE : Patients receive oxaliplatin IV 2 hour day 1 15 docetaxel IV 30 minute , floxuridine IV 24 hour , leucovorin calcium IV 24 hour day 1 , 8 , 15 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 26 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm gastric adenocarcinoma meeting follow criterion : Stage IV disease OR stage III disease restaged metastatic disease time surgery Unresectable disease Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No CNS metastases PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Bilirubin normal Creatinine ≤ 1.5 mg/dL Alkaline phosphatase ( AP ) , AST , ALT must meet 1 follow criterion : AP normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy No peripheral neuropathy &gt; grade 1 No history severe hypersensitivity reaction platinum agent ( e.g. , cisplatin carboplatin ) , fluoropyrimidines , drug formulate polysorbate 80 No concurrent serious illness would preclude study treatment compliance No active infection require intravenous antibiotic therapy No malignancy within past 5 year except cervical carcinoma situ , breast ductal carcinoma situ , colonic polyp , squamous cell basal cell carcinoma skin No clinically significant uncontrolled cardiac disease ( e.g. , congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia ) myocardial infarction within past 12 month PRIOR CONCURRENT THERAPY : No prior radiotherapy metastatic gastric carcinoma No prior chemotherapy metastatic gastric carcinoma Prior neoadjuvant adjuvant chemotherapy and/or radiotherapy allow complete therapy least 12 month study enrollment Chemotherapy may include taxane , platinum , fluoropyrimidinebased regimen At least 2 month since prior surgery recover No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>